Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 3
Journal homepage
16
Views
6
CrossRef citations to date
0
Altmetric
Cardiovascular Agents (Including Blood Products)

Overview: Recent Developments in Glaucoma Therapy

DF Woodward Departments of Biochemistry and Medicinal Chemistry Allergan Inc, 2525 Dupont Drive, Irvine, CA 92713–9534 USA
&
MF Chan Departments of Biochemistry and Medicinal Chemistry Allergan Inc, 2525 Dupont Drive, Irvine, CA 92713–9534 USA
Pages 287-304 | Published online: 02 Mar 2011

References to Primary Literature

  • Berrospi AR, Liebowrtz HM A new β-adrenergic blocking agent for treatment of glaucoma Arch. Ophthalmol. 1982 100 943.
  • Rushton A β-Adrenergic receptor subtypes and intraocular pressure [letter] Brit. J. Ophthalmol. 1983 67 557.
  • Mekki QA, Daves IB, Sinclair AJ, Turner P Effect of β2-selective adrenoceptor blockers on intraocular pressure in man Br. J. Clin. Pharmacol. 1986 21 596.
  • Chang S-C, Bundgaard H, Buur A, Lee VHL Improved corneal penetration of timolol by prodrugs as a means to reduce systemic load Invest. Ophthalmol. Vis. Sci. 1987 28 487.
  • Bodor NEL, Koussi A, Kano M, Nakamura T Improved delivery through biological membranes. 26. Design, synthesis and pharmacological activity of a novel chemical delivery system for β-adrenergic blocking agents J. Med. Chem. 1988 31 100.
  • Gorczynski RJ, Wong A Cardiovascular pharmacology of ACC-9089- a novel, ultra-short-acting, β-adrenergic receptor antagonist J. Cardiovasc. Pharmacol. 1984 6 555.
  • Maren TH, The development of ideas concerning the role of carbonic anhydrase in the secretion of aqueous humor: Relation to the treatment of glaucoma, Applied Pharmacology in the Medical Treatment of Glaucomas Drance SM J Grune & Stratton Inc 1984 325–355.
  • Maren TH Carbonic anhydrase: General perspectives and advances in glaucoma research Drug Development Res. 1987 10 255.
  • Maren TH, Jankowska L, Sanyal G, Edelhauser HF The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion Exp. Eye Res. 1983 36 457.
  • Maren TH, Bar-Ilan A, Caster KC, Katritzky AR The ocular pharmacology of methazolamide analogs: Distribution in the eye and effects on pressure following topical application J. Pharmacol. Exp. Ther. 1987 241 56.
  • Lewis RA, Schoenwald RD, Eller MG, Barfknecht CF, Phelps CD Ethoxzolamide analogue gel. A topical carbonic anhydrase inhibitor Arch. Ophthalmol. 1984 102 1821.
  • Lewis RA, Schoenwald RD, Barfknecht CF, Phelps CD Aminozolamide gel. A trial of a topical carbonic anhydrase inhibitor in ocular hypertension Arch. Ophthalmol. 1986 104 842.
  • Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF 6-Amino-2-ben-zothiazolesulfonamide: The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye Ophthalmology 1988 95 772.
  • Bar-Ilan A, Pessah NI, Maren TH Ocular penetration and hypotensive activity of the topically applied carbonic anhydrase inhibitor, L-645,151 J. Ocul. Pharmacol. 1986 2 109.
  • Woltersdorf OW, Schwam H, Bicking JB, Brown SL, Desolms SJ, Fishman DR, Graham SL, Gautheron PD, Hoffman JM, Larson RD, Lee SW, Michelson SR, Robb CM, Share NN, Shepard KL, Smith AM, Smith RL, Sondey JM, Strohmaier KM, Sugrue MF, Viader MP Topically active carbonic anhydrase inhibitors. 1. O-Acyl derivatives of 6-hydroxybenzothiazole-2-sul-fonamide J. Med. Chem. 1989 32 2486.
  • Graham SL, Shepard KL, Anderson PS, Baldwin JJ, Best DB, Christy ME, Freedman MB, Gautheron P, Habecker CN, Hoffman JM, Lyle PA, Michelson SR, Ponticello GS, Robb CM, Schwam H, Smith AM, Smith RL, Sondey JM, Strohmaier KM, Sugrue MF, Varga SL Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophene-sulfonamide derivatives with ocular hypotensive activity J. Med. Chem. 1989 32 2548.
  • Werner EB, Gerber DS, Yoder YJ Effect of a topical carbonic anhydrase inhibitor 6-hydroxybenzo[b]thiophene-2-sulfonamide on intraocular pressure in normotensive subjects Can. J. Ophthalmol. 1987 22 316.
  • Graham SL, Hoffman JM, Gautheron P, Michelson SR, Scholz TH, Schwam H, Shepard KL, Smith AM, Smith RL, Sondey JM, Sugrue MF Topically active carbonic anhydrase inhibitors. 3. Benzofuran- and indole-2-sulfonamides J. Med. Chem. 1990 33 749.
  • Baldwin JJ, Ponticello GS, Anderson PS, Christy ME, Murcko MA, Randall WC, Schwam H, Sugrue MF, Springer JP, Gautheron P, Grove J, Mallorga P, Vlader M-P, McKeever BM, Navia MA Thienothiopyran-2-sulfonamides: Novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma J. Med. Chem. 1989 32 2510.
  • Lippa EA, Von Denffer HA, Hofmann HM, Brunner-Ferber FL Local tolerance and activity of MK-927, a novel topical carbonic anhydrase inhibitor Arch. Ophthalmol. 1988 106 1694.
  • Higginbotham EJ, Kass MA, Lippa EA, Batenhorst RL, Panebianco DL, Wilensky JT MK-927: A topical carbonic anhydrase inhibitor. Dose response and duration of action Arch. Ophthalmol. 1990 108 65.
  • Lippa EA, Aasved H, Airaksinen PJ, Bertelsen T, Calissendorff B, Dithmer O, Eriksson L-O, Gustad L, Hovding G, Monestam E, Krogh E, Deasy D, Panebianco D, Tuulonen A Multi-dose, dose-response relationship for the topical carbonic anhydrase inhibitor MK-927 Arch. Ophthalmol. 1991 109 46.
  • Bron A, Lippa EA, Gunning F, Benichou C, Lesure P, Sirbat D, Royer J, Flament J, Clineschmidt C, Panebianco D, Buntinx A, Brunner-Ferber F, George J-L, Greve E Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors Sezolamide and MK-927 Arch. Ophthalmol. 1990 109 50.
  • Wang R-F, Serle JB, Podos SM, Sugrue MF The ocular hypotensive effect of the topical carbonic anhydrase inhibitor L-671,152 in glaucomatous monkeys Arch. Ophthalmol. 1990 108 511.
  • Sugrue MF, Mallorga P, Schwam H, Baldwin JJ, Ponticello GS Preclinical studies on L-671,152, a topically effective ocular hypotensive carbonic anhydrase inhibitor Br. J. Pharmacol. 1989 98 820P.
  • Podos SM, Serle JB Topically active carbonic anhydrase inhibitors for glaucoma Arch. Ophthalmol. 1991 109 38.
  • Sugrue MF, Gautheron P, Mallorga P, Nolan TE, Graham SL, Schwam H, Shepard KL, Smith RL L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals Br. J. Pharmacol. 1990 99 59.
  • Maren TH, Bar-Ilan A, Conroy CW, Brechue WF Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical route Exp. Eye Ees. 1990 50 27.
  • Yangisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T A novel potent vasoconstrictor peptide produced by vascular endothelial cells Nature 1988 322 411.
  • Ondetti MA Structural relationships of angiotensin converting-enzyme inhibitors to pharmacologic activity Circulation 1988 77 174.
  • Abrams KL, Brooks DE, Laratta Y, Barnhill MA, Frazier D Angiotensin converting enzyme system in the normal corneal eye: Pharmacological and physiological aspects J. Ocular Pharmacol. 1991 7 41.
  • Vita JB, Anderson JA, Hulem CD, Leopold IH Angiotensin-converting enzyme activity in ocular fluids Invest. Ophthalmol. Vis. Sci. 1981 20 255.
  • Weinreb RN, Sandman R, Ryder MI, Friberg TR Angiotensin-converting enzyme in human aqueous humor Arch. Ophthalmol. 1985 103 34.
  • Watkins RW, Baum T, Cedeno K, Smith EM, Yuen P-H, Ahn H-S, Barnett A Topical ocular hypotensive effects of the novel angiotensin converting enzyme inhibitor SCH 33861 in conscious rabbits J. Ocular Pharmacol. 1987 3 295.
  • Watkins RW, Baum T, Tedesco RP, Pula K, Barnett A Systemic effects resulting from topical ocular administration of SCH 33861, a novel ACE inhibitor ocular hypotensive agent J. Ocular Pharmacol. 1988 4 93.
  • Constad WH, Fiore P, Samson C, Cinotti A Use of an angiotensin converting enzyme inhibitor in ocular hypertension and primary open-angle glaucoma Am. J. Ophthalmol. 1988 105 674.
  • Greenlee WJ Renin inhibitors Med. Res. Rev. 1990 10 173.
  • Sramek SJ, Wallow IHL, Day RP, Erlich EN Ocular renin-angiotensin: Immunohistochemical evidence for the presence of prorenin in eye tissue Invest. Ophthalmol. Vis. Sci. 1988 29 749.
  • Giardina WJ, Kleinert MD, Ebert DM, Wismer CT, Chekal MA, Stein HH Intraocular pressure effects of the renin inhibitor ABBOTT-64662 diacetate in animals J. Ocular Pharmacol. 1990 6 75.
  • Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PBMWM Nonpeptide angiotensin II receptor antagonists IX. Antihypertensive activity in rats of DuP-753, an orally active antihypertensive agent J. Pharmacol. Exp. ther. 1990 252 726.
  • Krieglstein GK, Langham ME, Leydbecker W The peripheral and central neural actions of clonidine in normal and glaucomatous eyes Invest. Ophthalmol Vis. Sci. 1978 17 149.
  • Lee DA, Topper JE, Brubaker RF Effect of clonidine on aqueous humor flow in normal human eyes Exp. Eye Res. 1984 38 239.
  • Robin AL, Pollack IP, Faller DE Effect of topical ALO 2145 (p-amino clonidine hydrochloride) on the acute intraocular pressure rise after argon laser iridotomy Arch. Ophthalmol. 1987 105 1208.
  • Coleman AL, Robin AL, Pollack IP, Radikoff MT, Enger C, Mayer PR Cardiovascular and intraocular pressure effects and plasma concentrations of aproaclonidine Arch. Ophthalmol. 1990 108 1264.
  • Burke JA, Potter DE Ocular effects of a relatively selective α2-agonist (UK-14304–18) in cats, rabbits, and monkeys Curr. Eye Res. 1986 5 665.
  • Starr MS Further studies on the effect of prostaglandin on intraocular pressure in the rabbit Exp. Eye Res. 1971 11 170.
  • Camras CB, Bito LZ, Eakins KE Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits Invest. Ophthalmol. Vis. Sci. 1977 16 1125.
  • Bito LZ, Draga A, Blanco J, Camras CB Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes Invest. Ophthalmol. Vis. Sci. 1983 24 312.
  • Bito LZ Prostaglandins, old concepts and new perspectives Arch. Ophthalmol. 1987 105 1036.
  • Camras CB, Siebold EC, Lustgarten JS, Serle JB, Frisch SC, Podos SM, Bito LZ Maintained reduction of intraocular pressure by prostaglandin F2α-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucomatous patients Ophthalmol. 1989 96 1329.
  • Coleman RA, Humphrey PPA, Kennedy I Prostanoid receptors in smooth muscle: Further evidence for a proposed classification J. Autonom. Phannacol. 1982 3 35.
  • Woodward DF, Hawley SB, Williams LS, Ralston TL, Protzman CE, Spada CS, Nieves AL Studies on the ocular pharmacology of prostaglandin D2 Invest. Opthalmol. Vis. Sci. 1990 31 138.
  • Zimmerman TH Pilocarpine Ophtalmol. 1981 88 85.
  • Bundgaard H, Falch E, Larsen C, Mikkelson TJ Pilocarpine prodrugs 1. Synthesis, physicochemical properties and kinetics of lactonization of pilocarpic acid esters J. Pharm. Sci. 1986 75 36.
  • Hepler RS, Frank IM Marihuana smoking and intraocular pressure J. Am. Med. Assoc. 1974 217 1392.
  • Merritt JC, Perry DD, Russell DN, Jones BF Topical Δ9-tetrahydrocannabinol and aqueous dynamics in glaucoma J. Clin. Pharmacol. 1981 21 4675.
  • Cooler R, Gregg JM Effect of Δ−9-tetrahydrocannabinol on intraocular pressure in humans South. Med. J. 1977 70 951.
  • Tiedeman JS, Shields MB, Weber PA, Crow JW, Cocchetto DM, Harris WA, Howes JF Effect of synthetic cannabinoids on elevated intraocular pressure Ophthalmol. 1981 88 270.
  • Green K, Roth M Ocular effects of topical administration of Δ−9-tetrahydrocannabinol in man Arch. Ophthalmol. 1982 100 265.
  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, De Costa BR, Rice KC Cannabinnoid receptor localization in brain Proc. Nat. Acad. Sci. USA 1990 87 1933.
  • Howlett AC Regulation of adenylate cyclase in a cultured neuronal cell line by marijuana constituents, metabolites of Δ−9-tetrahydro-cannabinol and synthetic analogs having psychoactivity NIDA Res. Monograph. 1987 79 148.
  • Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI Structure of a cannabinoid receptor and functional expression of the cloned cDNA Nature 1990 346 561.
  • Lewis JM, Priddy T, Judd J, Gordon MO, Kass MA, Kolker AE, Becker B Intraocular pressure response to topical dexamethasone as a predictor for the development of primary open-angle glaucoma Am. J. Ophthalmol. 1988 106 607.
  • Southren AL, Gordon GG, Munnangi PR, Vittek J, Schwartz J, Monder C, Dunn MW, Weinstein BL Altered Cortisol metabolism in cells cultured from trabecular meshwork specimens obtained from patients with primary open-angle glaucoma Invest. Ophthalmol. Vis. Sci. 1983 24 1413.
  • Weinstein BL, Munnangi P, Gordon GG, Southren AL Defects in cortisol-metabolising enzymes in primary open-angle glaucoma Invest. Ophthalmol. Vis. Sci. 1985 26 890.
  • Weinstein BL, Gordon GG, Southren AL Potentiation of glucocorticoid activity by 5β-dihydrocortisol: Its role in glaucoma Science 1983 222 172.
  • Southren AL, Gordon GG, L'Hommedeu D, Ravikumar S, Dunn MW, Weinstein BL 5β-Dihydrocortisol: Possible mediator of the ocular hypertension in glaucoma Invest. Ophthalmol. Vis. Sci. 1985 26 393.
  • Hernandez MR, Weinstein BL, Dunn MW, Gordon GG, Southren AL The effect of dexamethasone on the synthesis of collagen in normal human trabecular meshwork explants Invest. Ophthalmol. Vis. Sci. 1985 26 1784.
  • Southren AL, Hernandez MR, L'Hommedieu D, Gordon GG, Weinstein BL Potentiation of collagen synthesis in explants of the rabbit eye by 5β-dihydrocortisol Invest. Ophthalmol. Vis. Sci. 1986 27 1757.
  • Green K, Phillips CI, Gore SM, Elijah RD, Bowman KA, Cullen P Ocular fluid dynamics response to topical RU-486, a steroid blocker Curr. Eye Res. 1985 4 605.
  • Green K, Cheeks L, Slagle T, Phillips CI Effects of mifepristone on rabbit intraocular pressure in the presence and absence of dexamethasone Ophthalmol. Res. 1990 22 247.
  • Tsukahara S, Sasaki T, Phillips CI, Gore SM Subconjunctival suspension of RU 486 lowers intraocular pressure in normal rabbits Br. J. Ophthalmol. 1986 70 451.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.